Study: Long use of any hormones poses cancer risk

April 1, 2012 By MARILYNN MARCHIONE , AP Chief Medical Writer

New research suggests that long-term use of any type of hormones to ease menopause symptoms can raise a woman's risk of breast cancer.

It is already known that taking pills that combine estrogen and progestin pills - the most common type of hormone therapy - can increase . But women who no longer have a uterus can take alone, which was thought to be safe and possibly even slightly beneficial in terms of cancer risk.

The new study suggests otherwise, if the pills are used for many years. It tracked the health of about 60,000 nurses and found that use of any kind of hormones for 10 years or more slightly raised the chances of developing .

"There's a continued increase in risk with longer durations of use and there does not appear to be a plateau," said study leader Dr. Wendy Chen of Brigham and Women's Hospital in Boston.

The hormone picture has been confusing, and the absolute risk of breast cancer for any woman taking remains small. Doctors say women should use the lowest dose needed for the shortest time possible.

"It's hard to be surprised that if you keep taking it, sooner or later it's going to raise risk," said Dr. Robert Clarke of Georgetown University's Lombardi Comprehensive Cancer Center.

The study was discussed Sunday at a cancer conference in Chicago.

Explore further: Elevated hormone levels add up to increased breast cancer risk

More information: Cancer conference: http://www.aacr.org

shares

Related Stories

Elevated hormone levels add up to increased breast cancer risk

October 21, 2011
Post-menopausal women with high levels of hormones such as estrogen or testosterone are known to have a higher risk of breast cancer. New research published in BioMed Central's open access journal Breast Cancer Research looked ...

Combo hormone therapy has increased breast cancer risk over estrogen alone

November 18, 2011
The debate about using menopausal hormone therapies to relieve symptoms in post-menopausal women has been ongoing. Is the combination therapy of estrogen and progestin better or worse than just giving women estrogen alone? ...

Stopping hormones might help breast cancer to regress

February 28, 2012
As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, ...

Menopausal hormone therapy and breast cancer risk

March 15, 2012
In the past decade, results from large prospective cohort studies and the Women's Health Initiative (WHI) randomized placebo-controlled hormone therapy trials have substantially changed thoughts about how estrogen alone and ...

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Mutant gene found to fuel cancer-promoting effects of inflammation

October 19, 2017
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.